ADAPY — Adaptimmune Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.60m
- $10.22m
- $178.03m
Brief: Adaptimmune Therapeutics Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement
Adaptimmune Therapeutics PLC reports results for the quarter ended in September - Earnings Summary
Adaptimmune rises on positive study data on cancer drug; job cuts
Adaptimmune Therapeutics PLC expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Centene, Rite Aid Corp, MSCI
Adaptimmune drops after ending partnership with GSK
Brief: Adaptimmune Enhances Its Pipeline Of Wholly Owned Cell Therapies For Cancer With Transfer Of Prame And Ny-Eso Target Programs From Gsk
U.S. STOCKS ON THE MOVE-OFS Credit, Nike, Elevance Health
U.S. STOCKS ON THE MOVE-CytoSorbents, Tapestry, Wayfair
Adaptimmune Therapeutics rises on promising cancer therapy data
Brief: Adaptimmune Reports Positive Data In Its Surpass Trial Outlines Plans For Advanced Clinical Development In Multiple Mage-A4 Positive Solid Tumors
Brief: Adaptimmune Therapeutics Reports Quarterly Loss Per Share Of $0.05
Adaptimmune Therapeutics PLC reports results for the quarter ended in March - Earnings Summary
Brief: Adaptimmune Reports First Quarter Financial Results
Adaptimmune Therapeutics PLC expected to post a loss of 22 cents a share - Earnings Preview
Brief: Adaptimmune Therapeutics PLC Files For Mixed Shelf Of Up To $400 Million – SEC Filing
U.S. RESEARCH ROUNDUP-Coupa Software, Entergy, Nektar Therapeutics
Adaptimmune Therapeutics PLC reports results for the quarter ended in December - Earnings Summary
Brief: Adaptimmune Reports Fourth Quarter And Full Year 2021 Financial Results And Business Update